SOA Wealth Advisors LLC. Sells 13,215 Shares of AbbVie Inc. $ABBV

Key Points

• SOA Wealth Advisors reduced its AbbVie position by 74.3% in the second quarter, selling 13,215 shares and retaining 4,566 shares valued at approximately $1.15 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with $3.65 in EPS and $16.99 billion in revenue, while revenue increased 10.2% year over year. The company also declared a $1.73 quarterly dividend, equivalent to a 2.8% annualized yield.
• Analysts remain broadly bullish, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $275.50. Growth prospects include neuroscience and post-Humira products, though valuation and pipeline setbacks remain key risks.

SOA Wealth Advisors LLC. trimmed its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 74.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,566 shares of the company's stock after selling 13,215 shares during the period. SOA Wealth Advisors LLC.'s holdings in AbbVie were worth $1,149,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ranch Capital Advisors Inc. boosted its stake in AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock worth $3,238,000 after purchasing an additional 4,017 shares during the period. Calamos Advisors LLC increased its position in shares of AbbVie by 3.4% during the fourth quarter. Calamos Advisors LLC now owns 466,290 shares of the company's stock valued at $106,543,000 after buying an additional 15,458 shares during the period. Wedge Capital Management L L P NC increased its position in shares of AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock valued at $33,865,000 after buying an additional 9,380 shares during the period. Axecap Investments LLC lifted its holdings in shares of AbbVie by 713.2% in the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company's stock worth $3,729,000 after buying an additional 14,313 shares in the last quarter. Finally, Legacy Edge Advisors LLC purchased a new stake in shares of AbbVie in the fourth quarter worth about $1,265,000. Institutional investors own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Trading Down 0.6%

Shares of ABBV opened at $249.20 on Friday. The company has a market cap of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. The stock has a 50-day moving average price of $244.94 and a 200-day moving average price of $226.12. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie's revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.

Analyst Ratings Changes

A number of equities analysts have recently commented on ABBV shares. Bank of America raised their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Wells Fargo & Company upped their target price on shares of AbbVie from $260.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, July 10th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Royal Bank Of Canada raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, July 10th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average price target of $275.50.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source